Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.30 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1506336 | 1.00 | ENPP2 (0.32) | ENPP2CRHBPCRHR2 | |
| SCHEMBL24609410 | 0.83 | NFE2L2 (0.31) | CRHBPCRHR2 | |
| SCHEMBL20580799 | 0.82 | NOS2 (0.37) | ENPP2 | |
| SCHEMBL29952243 | 0.79 | ENPP2 (0.31) | ENPP2 | |
| SCHEMBL1922455 | 0.79 | CCR1 (0.37) | — | |
| SCHEMBL1937542 | 0.79 | CHRNB2 (0.33) | ENPP2 | |
| SCHEMBL29911929 | 0.79 | CHRNB2 (0.33) | ENPP2 | |
| SCHEMBL29957469 | 0.77 | ENPP2 (0.30) | ENPP2 | |
| SCHEMBL13725857 | 0.77 | ENPP2 (0.30) | ENPP2 | |
| SCHEMBL13260555 | 0.77 | ENPP2 (0.30) | ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4280882-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2023-11-29 | — | — | EP | claimed |
| WO-2022159439-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| US-12595255-B2 | Heteroaryl-substituted imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-04-07 | — | — | US | disclosed |
| CN-118541371-A | Methionine adenosyltransferase 2A inhibitors for the treatment of MTAP deleted cancers | 勤浩医药（苏州）有限公司 | 2024-08-23 | — | — | CN | disclosed |
| US-20230373978-A1 | HETEROARYL-SUBSTITUTED IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-11-23 | — | — | US | disclosed |
| CN-116813647-A | Nitrogen-containing condensed ring STING regulator compound, preparation method and application | 上海凌达生物医药有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-113999266-B | Binuclear metal platinum complex and organic electroluminescent device | 深圳大学 | 2023-06-16 | — | — | CN | disclosed |
| CN-112778336-B | Nitrogen-containing condensed ring STING regulator compound, preparation method and application | 上海凌达生物医药有限公司 | 2023-05-05 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-110382496-B | Substituted pyrido [3,4-b ] indoles for the treatment of cartilage disorders | 赛诺菲 | 2022-08-09 | — | — | CN | disclosed |
| CN-113999266-A | Binuclear metal platinum complex and organic electroluminescent device | 深圳大学 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373978-A1 | HETEROARYL-SUBSTITUTED IMIDAZOLE DERIVATIVES | F3, ABL1, CFTR | ENPP2 4497/4885CRHBP 4793/4885CRHR2 3912/4885 |
| US-12595255-B2 | Heteroaryl-substituted imidazole derivatives | CLIC1, CYP2B6, CYP2D6 | ENPP2 4517/4885CRHBP 3777/4885CRHR2 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.